This confirms data from the Chinese study conducted in 2019 with patients with HER-2-positive tumors, in which reduced miR-21 expression was associated with the clinical response of the tumor but not the pathological response after neoadjuvant treatment [15]. This evidence concerns the gene ERBB2 and neoplasm.